130 related articles for article (PubMed ID: 12804048)
1. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP.
Breitz H; Wendt R; Stabin M; Bouchet L; Wessels B
Cancer Biother Radiopharm; 2003 Apr; 18(2):225-30. PubMed ID: 12804048
[TBL] [Abstract][Full Text] [Related]
2. High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation.
Rajendran JG; Eary JF; Bensinger W; Durack LD; Vernon C; Fritzberg A
J Nucl Med; 2002 Oct; 43(10):1383-90. PubMed ID: 12368378
[TBL] [Abstract][Full Text] [Related]
3. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
Breitz HB; Wendt RE; Stabin MS; Shen S; Erwin WD; Rajendran JG; Eary JF; Durack L; Delpassand E; Martin W; Meredith RF
J Nucl Med; 2006 Mar; 47(3):534-42. PubMed ID: 16513624
[TBL] [Abstract][Full Text] [Related]
4. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials.
Giralt S; Bensinger W; Goodman M; Podoloff D; Eary J; Wendt R; Alexanian R; Weber D; Maloney D; Holmberg L; Rajandran J; Breitz H; Ghalie R; Champlin R
Blood; 2003 Oct; 102(7):2684-91. PubMed ID: 12730103
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Dispenzieri A; Wiseman GA; Lacy MQ; Litzow MR; Anderson PM; Gastineau DA; Tefferi A; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Lust JA; Greipp PR; Rajkumar SV; Fonseca R; Witzig TE; Erlichman C; Sloan JA; Gertz MA
Leukemia; 2005 Jan; 19(1):118-25. PubMed ID: 15526021
[TBL] [Abstract][Full Text] [Related]
6. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S
Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma.
Bayouth JE; Macey DJ; Kasi LP; Garlich JR; McMillan K; Dimopoulos MA; Champlin RE
J Nucl Med; 1995 May; 36(5):730-7. PubMed ID: 7738641
[TBL] [Abstract][Full Text] [Related]
8. Radiation dose distribution within the bone marrow of patients receiving holmium-166-labeled-phosphonate for marrow ablation.
Bayouth JE; Macey DJ; Boyer AL; Champlin RE
Med Phys; 1995 Jun; 22(6):743-53. PubMed ID: 7565363
[TBL] [Abstract][Full Text] [Related]
9. Estimation of human absorbed dose for (166)Ho-PAM: comparison with (166)Ho-DOTMP and (166)Ho-TTHMP.
Vaez-Tehrani M; Zolghadri S; Yousefnia H; Afarideh H
Br J Radiol; 2016 Oct; 89(1066):20160153. PubMed ID: 27524266
[TBL] [Abstract][Full Text] [Related]
10. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies.
Bartlett ML; Webb M; Durrant S; Morton AJ; Allison R; Macfarlane DJ
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1470-7. PubMed ID: 12397466
[TBL] [Abstract][Full Text] [Related]
11. In focus: (166) Ho-DOTMP in the pretransplant treatment of multiple myeloma.
Clapp K
Clin Adv Hematol Oncol; 2004 Nov; 2(11):753-4. PubMed ID: 16170894
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow transplantation in dogs after radio-ablation with a new Ho-166 amino phosphonic acid bone-seeking agent (DOTMP).
Parks NJ; Kawakami TG; Avila MJ; White R; Cain GR; Raaka SD; Hornoff W; Fisher P; Moore P; Seibert JA
Blood; 1993 Jul; 82(1):318-25. PubMed ID: 8324232
[TBL] [Abstract][Full Text] [Related]
13. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Dispenzieri A; Wiseman GA; Lacy MQ; Hayman SR; Kumar SK; Buadi F; Dingli D; Laumann KM; Allred J; Geyer SM; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Johnston PB; Hogan WJ; Gertz MA
Am J Hematol; 2010 Jun; 85(6):409-13. PubMed ID: 20513117
[TBL] [Abstract][Full Text] [Related]
14. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings.
Behr TM; Béhé M; Sgouros G
Cancer Biother Radiopharm; 2002 Aug; 17(4):445-64. PubMed ID: 12396708
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic, Dosimetry and Toxicity Study of ¹⁷⁷Lu-EDTMP in Patients: Phase 0/I study.
Bal C; Arora G; Kumar P; Damle N; Das T; Chakraborty S; Banerjee S; Venkatesh M; Zaknun JJ; Pillai MR
Curr Radiopharm; 2016; 9(1):71-84. PubMed ID: 25771371
[TBL] [Abstract][Full Text] [Related]
16. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
17. A preclinical investigation of the saturation and dosimetry of 153Sm-DOTMP as a bone-seeking radiopharmaceutical.
Simón J; Frank RK; Crump DK; Erwin WD; Ueno NT; Wendt RE
Nucl Med Biol; 2012 Aug; 39(6):770-6. PubMed ID: 22459336
[TBL] [Abstract][Full Text] [Related]
18. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study.
Smits ML; Nijsen JF; van den Bosch MA; Lam MG; Vente MA; Mali WP; van Het Schip AD; Zonnenberg BA
Lancet Oncol; 2012 Oct; 13(10):1025-34. PubMed ID: 22920685
[TBL] [Abstract][Full Text] [Related]
19. Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation.
Wong JY; Liu A; Schultheiss T; Popplewell L; Stein A; Rosenthal J; Essensten M; Forman S; Somlo G
Biol Blood Marrow Transplant; 2006 Mar; 12(3):306-15. PubMed ID: 16503500
[TBL] [Abstract][Full Text] [Related]
20. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
